Free Trial
OTCMKTS:ACUR

Acura Pharmaceuticals (ACUR) Stock Price, News & Analysis

Acura Pharmaceuticals logo
$0.0017 0.00 (0.00%)
(As of 11/20/2024 ET)

About Acura Pharmaceuticals Stock (OTCMKTS:ACUR)

Key Stats

Today's Range
$0.0017
$0.0017
50-Day Range
N/A
52-Week Range
$0.00
$0.58
Volume
940 shs
Average Volume
274 shs
Market Capitalization
$112,795.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc. and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was formerly known as Halsey Drug Co., Inc. The company was incorporated in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals, Inc. operates as a subsidiary of Abuse Deterrent Pharma, LLC.

Receive ACUR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acura Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACUR Stock News Headlines

Trump said you could learn something from this man
Early Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement.
See More Headlines

ACUR Stock Analysis - Frequently Asked Questions

Acura Pharmaceuticals' stock was trading at $0.0001 on January 1st, 2024. Since then, ACUR stock has increased by 1,600.0% and is now trading at $0.0017.
View the best growth stocks for 2024 here
.

Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) issued its quarterly earnings data on Friday, February, 28th. The specialty pharmaceutical company reported $0.00 EPS for the quarter. The specialty pharmaceutical company earned $1.32 million during the quarter.

Acura Pharmaceuticals subsidiaries include Acura Pharmaceutical Technologies Inc..

Shares of ACUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Acura Pharmaceuticals investors own include Denali Therapeutics (DNLI), Ekso Bionics (EKSO), VIVUS (VVUS), Corbus Pharmaceuticals (CRBP), Fulcrum Therapeutics (FULC) and Adamis Pharmaceuticals (ADMP).

Company Calendar

Last Earnings
2/28/2020
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:ACUR
Previous Symbol
NASDAQ:ACUR
CUSIP
00509L70
Employees
10
Year Founded
1935

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.56 million

Miscellaneous

Free Float
52,947,000
Market Cap
$112,795.00
Optionable
Not Optionable
Beta
1.61

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (OTCMKTS:ACUR) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners